| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 13 | 2022 | 92 | 3.970 |
Why?
|
| Proteasome Inhibitors | 5 | 2019 | 29 | 2.560 |
Why?
|
| Protein Disulfide-Isomerases | 5 | 2022 | 27 | 2.380 |
Why?
|
| Antineoplastic Agents | 14 | 2020 | 1070 | 2.060 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 332 | 1.330 |
Why?
|
| Small Molecule Libraries | 2 | 2018 | 53 | 1.240 |
Why?
|
| Bortezomib | 6 | 2019 | 45 | 1.230 |
Why?
|
| Histone Deacetylase Inhibitors | 4 | 2022 | 116 | 1.040 |
Why?
|
| High-Throughput Screening Assays | 3 | 2018 | 48 | 0.780 |
Why?
|
| Cell Line, Tumor | 17 | 2020 | 1851 | 0.730 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2020 | 4 | 0.730 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2019 | 17 | 0.700 |
Why?
|
| Boronic Acids | 3 | 2014 | 40 | 0.690 |
Why?
|
| Mice | 23 | 2022 | 8474 | 0.690 |
Why?
|
| Pyrazines | 3 | 2014 | 46 | 0.680 |
Why?
|
| Plasmacytoma | 1 | 2018 | 15 | 0.650 |
Why?
|
| Indenes | 1 | 2018 | 6 | 0.650 |
Why?
|
| Colonic Neoplasms | 5 | 2011 | 299 | 0.640 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2018 | 63 | 0.640 |
Why?
|
| Mice, SCID | 7 | 2020 | 238 | 0.640 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2018 | 72 | 0.630 |
Why?
|
| Lymphoma, B-Cell | 1 | 2018 | 40 | 0.630 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 3 | 2008 | 17 | 0.630 |
Why?
|
| Glioblastoma | 2 | 2020 | 219 | 0.610 |
Why?
|
| Glutaminase | 1 | 2017 | 7 | 0.590 |
Why?
|
| Thiadiazoles | 1 | 2017 | 7 | 0.590 |
Why?
|
| Apoptosis | 8 | 2018 | 1641 | 0.590 |
Why?
|
| Benzeneacetamides | 1 | 2017 | 11 | 0.590 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 332 | 0.560 |
Why?
|
| Oligopeptides | 1 | 2017 | 152 | 0.550 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 371 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 756 | 0.530 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 3 | 2011 | 19 | 0.510 |
Why?
|
| Animals | 24 | 2022 | 20881 | 0.510 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 69 | 0.470 |
Why?
|
| Mice, Nude | 7 | 2020 | 294 | 0.440 |
Why?
|
| Prostatic Neoplasms | 4 | 2008 | 778 | 0.440 |
Why?
|
| Tumor Cells, Cultured | 5 | 2018 | 852 | 0.430 |
Why?
|
| Pyrimidine Nucleosides | 1 | 2012 | 1 | 0.430 |
Why?
|
| Tubercidin | 1 | 2012 | 2 | 0.430 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2012 | 5 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 331 | 0.420 |
Why?
|
| Drug Synergism | 6 | 2020 | 260 | 0.420 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 659 | 0.400 |
Why?
|
| HSP40 Heat-Shock Proteins | 2 | 2022 | 8 | 0.390 |
Why?
|
| Bone Neoplasms | 3 | 2008 | 100 | 0.390 |
Why?
|
| Spectrum Analysis | 1 | 2011 | 81 | 0.390 |
Why?
|
| Cell Survival | 5 | 2019 | 901 | 0.380 |
Why?
|
| Quinazolines | 1 | 2011 | 70 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2019 | 304 | 0.370 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2010 | 6 | 0.370 |
Why?
|
| Immunoglobulin E | 1 | 2010 | 91 | 0.360 |
Why?
|
| Humans | 30 | 2022 | 68618 | 0.350 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 201 | 0.340 |
Why?
|
| Autophagy | 1 | 2011 | 208 | 0.340 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1174 | 0.320 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2019 | 99 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2020 | 231 | 0.300 |
Why?
|
| Bone Marrow | 2 | 2008 | 168 | 0.290 |
Why?
|
| Oncogene Protein v-akt | 1 | 2007 | 25 | 0.290 |
Why?
|
| Neoplastic Stem Cells | 3 | 2013 | 84 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 511 | 0.280 |
Why?
|
| Translocation, Genetic | 2 | 2018 | 74 | 0.260 |
Why?
|
| Oncogenes | 2 | 2018 | 71 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 468 | 0.250 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2013 | 65 | 0.220 |
Why?
|
| CDC2 Protein Kinase | 2 | 2013 | 13 | 0.210 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2013 | 71 | 0.210 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 138 | 0.200 |
Why?
|
| Hydroxamic Acids | 1 | 2022 | 84 | 0.200 |
Why?
|
| Quinacrine | 2 | 2011 | 10 | 0.200 |
Why?
|
| Green Fluorescent Proteins | 2 | 2011 | 200 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 170 | 0.190 |
Why?
|
| RNA Polymerase II | 1 | 2020 | 14 | 0.180 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 261 | 0.180 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2020 | 21 | 0.180 |
Why?
|
| Forkhead Transcription Factors | 2 | 2013 | 94 | 0.180 |
Why?
|
| Acetylation | 1 | 2020 | 94 | 0.180 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 42 | 0.180 |
Why?
|
| Azoles | 1 | 2019 | 7 | 0.180 |
Why?
|
| Gene Silencing | 1 | 2020 | 137 | 0.170 |
Why?
|
| Up-Regulation | 2 | 2020 | 682 | 0.170 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2013 | 175 | 0.170 |
Why?
|
| Histones | 1 | 2020 | 111 | 0.170 |
Why?
|
| Tumor Burden | 1 | 2019 | 132 | 0.170 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 226 | 0.170 |
Why?
|
| Amides | 1 | 2019 | 86 | 0.170 |
Why?
|
| Mice, Hairless | 1 | 2018 | 1 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 116 | 0.160 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2018 | 25 | 0.160 |
Why?
|
| Cell Line | 2 | 2019 | 1752 | 0.160 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 420 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 132 | 0.160 |
Why?
|
| Molecular Structure | 1 | 2019 | 397 | 0.160 |
Why?
|
| Isoenzymes | 1 | 2019 | 308 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 615 | 0.150 |
Why?
|
| Cell Respiration | 1 | 2017 | 47 | 0.150 |
Why?
|
| Cell Death | 3 | 2013 | 329 | 0.150 |
Why?
|
| Cell Hypoxia | 3 | 2013 | 92 | 0.140 |
Why?
|
| Enzyme Activation | 3 | 2013 | 791 | 0.140 |
Why?
|
| Transplantation, Heterologous | 3 | 2011 | 122 | 0.140 |
Why?
|
| Fluorouracil | 3 | 2011 | 130 | 0.140 |
Why?
|
| Signal Transduction | 6 | 2013 | 2689 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2011 | 561 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 597 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1745 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 2791 | 0.130 |
Why?
|
| Energy Metabolism | 1 | 2017 | 222 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2013 | 331 | 0.130 |
Why?
|
| HCT116 Cells | 2 | 2013 | 63 | 0.120 |
Why?
|
| Male | 10 | 2020 | 37321 | 0.120 |
Why?
|
| Cell Nucleus | 2 | 2013 | 305 | 0.120 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 160 | 0.120 |
Why?
|
| Tumor Microenvironment | 2 | 2013 | 213 | 0.120 |
Why?
|
| Neoplasms | 2 | 2019 | 1667 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2011 | 114 | 0.120 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 1033 | 0.110 |
Why?
|
| Pyrimidines | 2 | 2013 | 178 | 0.110 |
Why?
|
| Genes, myc | 1 | 2013 | 26 | 0.110 |
Why?
|
| bcl-X Protein | 1 | 2013 | 36 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 376 | 0.110 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2013 | 34 | 0.110 |
Why?
|
| Bone and Bones | 2 | 2010 | 145 | 0.110 |
Why?
|
| Bone Marrow Cells | 2 | 2011 | 217 | 0.110 |
Why?
|
| Myeloablative Agonists | 1 | 2012 | 4 | 0.100 |
Why?
|
| Melphalan | 1 | 2012 | 15 | 0.100 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2012 | 10 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2012 | 111 | 0.100 |
Why?
|
| Mitochondria | 1 | 2017 | 643 | 0.100 |
Why?
|
| Flavonoids | 1 | 2012 | 109 | 0.100 |
Why?
|
| Piperidines | 1 | 2012 | 123 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2011 | 954 | 0.100 |
Why?
|
| Hydroxychloroquine | 1 | 2011 | 14 | 0.100 |
Why?
|
| Phagosomes | 1 | 2011 | 19 | 0.100 |
Why?
|
| Caspase 8 | 1 | 2011 | 40 | 0.100 |
Why?
|
| Biomarkers | 1 | 2017 | 1593 | 0.100 |
Why?
|
| HT29 Cells | 1 | 2011 | 42 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 28 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 64 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 272 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 149 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 95 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 110 | 0.090 |
Why?
|
| Hypercalcemia | 1 | 2010 | 34 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 498 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2010 | 63 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 268 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2011 | 231 | 0.090 |
Why?
|
| Anemia | 1 | 2010 | 104 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 121 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2013 | 1200 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 163 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 307 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 848 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 216 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 194 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1174 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 475 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2008 | 24 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 508 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 334 | 0.070 |
Why?
|
| Tyrphostins | 1 | 2007 | 13 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2007 | 25 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2007 | 98 | 0.070 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2007 | 45 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 235 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2077 | 0.070 |
Why?
|
| Middle Aged | 5 | 2012 | 21147 | 0.070 |
Why?
|
| Pyridines | 3 | 2013 | 261 | 0.070 |
Why?
|
| Aged | 3 | 2017 | 14862 | 0.060 |
Why?
|
| RNA, Small Interfering | 3 | 2011 | 434 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 26 | 0.060 |
Why?
|
| Cell Movement | 3 | 2013 | 630 | 0.060 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2011 | 19 | 0.050 |
Why?
|
| Phenylurea Compounds | 2 | 2011 | 31 | 0.050 |
Why?
|
| Niacinamide | 2 | 2011 | 31 | 0.050 |
Why?
|
| Benzenesulfonates | 2 | 2011 | 30 | 0.050 |
Why?
|
| Camptothecin | 2 | 2011 | 39 | 0.050 |
Why?
|
| Forkhead Box Protein O3 | 2 | 2013 | 10 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2011 | 174 | 0.050 |
Why?
|
| Female | 6 | 2012 | 38074 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2012 | 7029 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2004 | 617 | 0.040 |
Why?
|
| Peptides, Cyclic | 1 | 2019 | 35 | 0.040 |
Why?
|
| Drug Design | 1 | 2020 | 107 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 70 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2013 | 447 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2019 | 66 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2011 | 489 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 95 | 0.040 |
Why?
|
| Adult | 4 | 2012 | 21403 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 567 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2550 | 0.040 |
Why?
|
| Adolescent | 2 | 2008 | 8912 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 411 | 0.030 |
Why?
|
| Prognosis | 2 | 2011 | 2093 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 718 | 0.030 |
Why?
|
| Cyclin B1 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2013 | 36 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2013 | 85 | 0.030 |
Why?
|
| Bystander Effect | 1 | 2013 | 10 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 175 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 99 | 0.030 |
Why?
|
| Protein Transport | 1 | 2013 | 280 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 145 | 0.030 |
Why?
|
| Transplantation, Isogeneic | 1 | 2011 | 19 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 52 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2011 | 8 | 0.020 |
Why?
|
| Etoposide | 1 | 2011 | 64 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 41 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 349 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2011 | 57 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 40 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 42 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 83 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 73 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 78 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2011 | 52 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2011 | 155 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 64 | 0.020 |
Why?
|
| ras Proteins | 1 | 2011 | 102 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 266 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 532 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 255 | 0.020 |
Why?
|
| Femur | 1 | 2010 | 113 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2011 | 111 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2009 | 16 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 109 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 369 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 1056 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 536 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2011 | 432 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 742 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2012 | 7277 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 118 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 800 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 981 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 196 | 0.020 |
Why?
|
| Serine | 1 | 2008 | 99 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1465 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1140 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 592 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 465 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1213 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 1027 | 0.020 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2004 | 2 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 16 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2004 | 78 | 0.010 |
Why?
|
| Endothelium | 1 | 2004 | 98 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2004 | 51 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 3259 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 4655 | 0.010 |
Why?
|
| Osteoblasts | 1 | 2004 | 99 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2004 | 324 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 223 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 4848 | 0.010 |
Why?
|
| Young Adult | 1 | 2008 | 5717 | 0.010 |
Why?
|